Home
HelpTest Code CDAU7 Drug Abuse Survey with Confirmation, Panel 9, Random, Urine
Reporting Name
Confirmed Drug Abuse Panel 9, UUseful For
Detecting drug abuse involving, amphetamines, barbiturates, benzodiazepines, cocaine, ethanol, methadone, opiates, phencyclidine, and tetrahydrocannabinol
This test is intended to be used in a setting where the test results can be used definitively to make a diagnosis.
This test is not intended for use in employment-related testing.
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| OPATU | Opiate Confirmation, U | Yes | No |
| AMPHU | Amphetamines Confirmation, U | Yes | No |
| BARBU | Barbiturates Confirmation, U | Yes | No |
| COKEU | Cocaine and metabolite Conf, U | Yes | No |
| ETOH | Ethanol, U | No | No |
| MTDNU | Methadone Confirmation, U | Yes | No |
| PCPU | Phencyclidine Confirmation, U | Yes | No |
| THCU | Carboxy-THC Confirmation, U | Yes | No |
| BNZU | Benzodiazepines Confirmation, U | Yes | No |
Testing Algorithm
Testing begins with screening tests for alcohol and drugs of abuse. Positives are confirmed and quantitated by definitive methods (gas chromatography with flame ionization detector for ethanol; gas chromatography mass spectrometry for barbiturates, cocaine and metabolites, methadone, and phencyclidine) at an additional charge. Amphetamines, benzodiazepines, opiates, and tetrahydrocannabinol metabolite that screen positive will be quantified with liquid chromatography tandem mass spectrometry at an additional charge.
Method Name
Enzymatic Assay/Immunoassay
ETOH: Headspace Gas Chromatography with Flame Ionization Detector (HSGC-FID)
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
UrineOrdering Guidance
For situations where chain-of-custody is required, a Chain-of-Custody Kit (T282) is available. For chain-of-custody testing, order CDA7X / Drug Abuse Survey with Confirmation, Panel 9, Chain of Custody, Random, Urine.
Additional Testing Requirements
If urine creatinine is required or adulteration of the sample is suspected, the following test should be requested, ADULT / Adulterants Survey, Urine. For additional information, please refer to ADULT / Adulterants Survey, Random, Urine.
Specimen Required
Supplies: Urine Container, 60 mL (T313)
Collection Container/Tube: Plastic urine container
Submission Container/Tube: Plastic, 60-mL urine bottle
Specimen Volume: 30 mL
Collection Instructions:
1. Collect a random urine specimen.
2. Submit 30 mL in 1 plastic bottle.
3. No preservative.
Additional Information:
1. No specimen substitutions.
2. Additional drug panels and specific requests are available. Call 800-533-1710 or 507-266-5700.
3. Submitting less than 30 mL will compromise our ability to perform all necessary testing.
Specimen Minimum Volume
15 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Urine | Refrigerated (preferred) | 7 days | |
| Frozen | 14 days |
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Reference Values
Negative
Screening cutoff concentrations
Amphetamines: 500 ng/mL
Barbiturates: 200 ng/mL
Benzodiazepines: 100 ng/mL
Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL
Ethanol: 10 mg/dL
Methadone metabolite: 300 ng/mL
Opiates: 300 ng/mL
Phencyclidine: 25 ng/mL
Tetrahydrocannabinol carboxylic acid: 50 ng/mL
This report is intended for use in clinical monitoring or management of patients. It is not intended for use in employment-related testing.
Day(s) Performed
Monday through Saturday
CPT Code Information
80307
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| CDAU7 | Confirmed Drug Abuse Panel 9, U | 87428-9 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 30909 | Alcohol | 34180-0 |
| 2573 | Amphetamines | 43983-6 |
| 2574 | Barbiturates | 70155-7 |
| 2575 | Benzodiazepines | 16195-0 |
| 21652 | Cocaine | 19359-9 |
| 4435 | Methadone metabolite | 16246-1 |
| 2577 | Opiates | 18390-5 |
| 2578 | Phencyclidine | 18392-1 |
| 2664 | Tetrahydrocannabinol | 19415-9 |
| 20672 | Chain of Custody | 77202-0 |
Clinical Information
This assay was designed to screen by immunoassay and confirm the following drugs, by either gas chromatography-mass spectrometry (GC-MS), gas chromatography-flame ionization detection (GC-FID), or liquid chromatography-tandem mass spectrometry (LC-MS/MS):
-Amphetamines
-Barbiturates
-Benzodiazepines
-Cocaine
-Ethanol
-Opiates
-Methadone
-Phencyclidine
-Tetrahydrocannabinol
This test uses the simple screening technique which involves immunoassay testing for drugs by class. All positive immunoassay screening results will be confirmed by the definitive assay available and is described in each individual reflex test (eg, AMPHU / Amphetamines Confirmation, Random, Urine). All positive screening results are confirmed by either GC-MS, GC-FID, or LC-MS/MS and quantitated before a positive result is reported.
Interpretation
A positive result indicates that the patient has used the drugs detected in the recent past. See individual tests (eg, AMPHU / Amphetamines Confirmation, Random, Urine) for more information.
For information about drug testing, including estimated detection times, see Drugs of Abuse Testing.
Cautions
The test does not screen for drug classes other than those listed above. More comprehensive screening is available using the serum or urine drug screens (DSS / Drug Screen, Prescription/Over the Counter, Serum or PDSU / Drug Screen, Prescription/Over the Counter, Random, Urine).
Method Description
The amphetamines, barbiturates, benzodiazepines, cocaine, methadone metabolite, opiates, phencyclidine, and tetrahydrocannabinol metabolite assays are based on the kinetic interaction of microparticles in a solution (KIMS) as measured by changes in light transmission. In the absence of sample drug, soluble drug conjugates bind to antibody-bound microparticles, causing the formation of particle aggregates. As the aggregation reaction proceeds in the absence of sample drug, the absorbance increases. When a urine sample contains the drug in question, this drug competes with the drug derivative conjugate for microparticle-bound antibody. Antibody bound to sample drug is no longer available to promote particle aggregation, and subsequent particle lattice formation is inhibited. The presence of sample drug diminishes the increasing absorbance in proportion to the concentration of drug in the sample. Sample drug content is determined relative to the value obtained for a known cutoff concentration of drug.(Package inserts: EDDP Specific Urine Enzyme Immunoassay. Immunalysis; 09/2018; AMPS2 cobas. Roche Diagnostics; V 10.0 09/2018; BARB cobas. Roche Diagnostics; V 13.0 09/2021; THC2 cobas. Roche Diagnostics; V 13.0 03/2022; BNZ2 cobas. Roche Diagnostics; V 2.0 04/2024; COC2 cobas. Roche Diagnostics; V 9.0 03/2019; ETOH2 cobas. Roche Diagnostics; V 16.0 06/2022; OPI2 cobas. Roche Diagnostics; V 16.0 01/2022; PCP cobas. Roche Diagnostics; V 13.0 09/2021)
ETOH Confirmation
Specimens are analyzed and quantified by headspace gas chromatography with flame ionization detection.(Baselt RC. Disposition of Toxic Drugs and Chemicals in Man, 10th edition, Biomedical Publications; 2014:2211)